Login to Your Account

Pharma: Clinic Roundup

Thursday, June 20, 2013
• ALK-Abello A/S, of Horsholm, Denmark, reported a positive outcome of the first of two pivotal Phase III trials of its allergy immunotherapy tablet for the treatment of house dust mite-induced respiratory diseases, demonstrating that the treatment has a significant clinical effect in allergic rhinitis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription